2. Search Result
Search Result
Results for "

systolic

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109128
    Danicamtiv
    1 Publications Verification

    MYK-491

    		 Myosin Cancer
    Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
    Danicamtiv
  • HY-114252
    Strophanthidin

    		Na+/K+ ATPase Cardiovascular Disease
    Strophanthidin is a naturally available cardiac glycoside . Strophanthidin 0.1 and 1 nmol/L increases and 1~100 μmol/L inhibits the Na+/K+-ATPase activities, but Strophanthidin 10 and 100 nmol/L does not affect Na+/K+-ATPase activities in cardiac sarcolemmal . Strophanthidin increases both diastolic and systolic intracellular Ca 2+ concentration .
    Strophanthidin
  • HY-124873
    SERCA2a activator 1

    		Calcium Channel Cardiovascular Disease
    SERCA2a activator 1 (Compound A) is a sarco/endoplasmic reticulum Ca 2+-dependent ATPase 2a (SERCA2a) activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure .
    SERCA2a activator 1
  • HY-131948
    3-Chlorodiphenylamine

    		Potassium Channel Cardiovascular Disease
    3-Chlorodiphenylamine is a high affinity Ca 2+ sensitizer of cardiac muscle. 3-Chlorodiphenylamine is based on diphenylamine and binds to the isolated N-domain of cardiac troponin C (cTnC) (Kd=6 µM). 3-Chlorodiphenylamine is an excellent starting scaffold for the development of more potent Ca 2+-sensitizing compounds due to its small size, and can be used for systolic heart failure research .
    3-Chlorodiphenylamine
  • HY-B0251
    Eplerenone
    5 Publications Verification

    Epoxymexrenone

    		 Mineralocorticoid Receptor Endogenous Metabolite Cardiovascular Disease Cancer
    Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .
    Eplerenone
  • HY-114252R
    Strophanthidin (Standard)

    		Na+/K+ ATPase Cardiovascular Disease
    Strophanthidin (Standard) is the analytical standard of Strophanthidin. This product is intended for research and analytical applications. Strophanthidin is a naturally available cardiac glycoside . Strophanthidin 0.1 and 1 nmol/L increases and 1~100 μmol/L inhibits the Na+/K+-ATPase activities, but Strophanthidin 10 and 100 nmol/L does not affect Na+/K+-ATPase activities in cardiac sarcolemmal . Strophanthidin increases both diastolic and systolic intracellular Ca2+ concentration .
    Strophanthidin (Standard)
  • HY-N1115
    Tubotaiwine

    (+)-Tubotaiwine; NSC 306222; Tubotaiwin

    		 Others Cardiovascular Disease
    Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .
    Tubotaiwine
  • HY-121259
    Doxorubicinol

    Adriamycinol; DXR-OL

    		 Endogenous Metabolite Cardiovascular Disease
    Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
    Doxorubicinol
  • HY-18347
    Conivaptan

    YM 087 free base

    		 Vasopressin Receptor Cardiovascular Disease
    Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .
    Conivaptan
  • HY-137396
    6β-Hydroxy Eplerenone

    		Endogenous Metabolite Cardiovascular Disease
    6β-Hydroxy Eplerenone is a metabolite of Eplerenone (HY-B0251). 6β-Hydroxy Eplerenone plays an important role in the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .
    6β-Hydroxy Eplerenone
  • HY-161834
    RG100204

    		Aquaporin Infection Inflammation/Immunology
    RG100204 is an orally active AQP9 inhibitor with anti-inflammatory activity. RG100204 can alleviate sepsis-induced cardiac dysfunction (both systolic and diastolic), improve renal dysfunction, and reduce the elevation of LDH, a marker of cellular injury .
    RG100204
  • HY-106667
    DL 071IT

    		Adrenergic Receptor Cardiovascular Disease Endocrinology
    DL 071IT is a potent non-selective beta-adrenergic receptor blocker. DL 071IT exhibits intrinsic sympathomimetic activity and weak membrane stabilizing activity. DL 071IT reduces exercise heart rate and systolic blood pressure, and even significantly lowers resting heart rate .
    DL 071IT
  • HY-126401
    Elgodipine

    IQB-875 free base

    		 Calcium Channel Cardiovascular Disease
    Elgodipine (IQB-875 free base) is an orally active dihydropyridine calcium antagonist and an antianginal compound. Elgodipine inhibits both T- and L-type calcium channels (IC50: 32 and 2.3 nM). Elgodipine lowers systemic vascular resistance and improves systolic cardiac function .
    Elgodipine
  • HY-161608
    Myosin modulator 1

    		Myosin Cardiovascular Disease
    Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 1
  • HY-161609
    Myosin modulator 2

    		Myosin Cardiovascular Disease
    Myosin modulator 2 (Compound B172) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 2.013, 2.94 and 20.93 μM, respectively. Myosin modulator 2 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 2
  • HY-19867A
    Burixafor hydrobromide
    1 Publications Verification

    TG-0054 hydrobromide

    		 CXCR Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization . Burixafor hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction .
    Burixafor hydrobromide
  • HY-147384
    CXL-1020

    		Calcium Channel Cardiovascular Disease
    CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca 2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure .
    CXL-1020
  • HY-16056
    Arbutamine

    		Adrenergic Receptor Cardiovascular Disease
    Arbutamine is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine can be used for cardiac stress agent .
    Arbutamine
  • HY-16056A
    Arbutamine hydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    Arbutamine hydrochloride is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine hydrochloride stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine hydrochloride provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine hydrochloride can be used for cardiac stress agent .
    Arbutamine hydrochloride
  • HY-123801
    MIDD0301

    GL-II-93

    		 GABA Receptor Others
    MIDD0301 (GL-II-93) is an orally effective, anti-asthmatic positive allosteric modulator of GABAA receptor. MIDD0301 had no significant adverse immune reactions at repeated doses and was better than Prednisone (HY-B0214). MIDD0301 relaxes histamine contractions in guinea pig and human tracheal smooth muscle for the study of bronchial systolic diseases .
    MIDD0301
  • HY-B0251R
    Eplerenone (Standard)
    5 Publications Verification

    Epoxymexrenone (Standard)

    		 Mineralocorticoid Receptor Endogenous Metabolite Cardiovascular Disease Cancer
    Eplerenone (Standard) is the analytical standard of Eplerenone. This product is intended for research and analytical applications. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .
    Eplerenone (Standard)
  • HY-W145695
    Chitoheptaose

    		Biochemical Assay Reagents Inflammation/Immunology
    Chitoheptaose is a chitosan oligosaccharide. Chitoheptaose is capable of extracting exoskeletons from crustaceans, such as the shells of crabs, shrimp and lobsters. Chitoheptaose has antioxidant, anti-inflammatory and anti-apoptotic activities and can be used in the study of myocarditis. Chitoheptaose has cardioprotective effects and improves cardiac parameters (left ventricular internal size, end-systolic and end-diastolic, ejection fraction and shortening fraction), inflammatory cytokines (IL-1β) in vanishing models .
    Chitoheptaose
  • HY-123226
    TA-606

    		Angiotensin Receptor Cardiovascular Disease
    TA-606 is a potent and orally active angiotensin II-receptor antagonist. TA-606 shows antihypertensive efficacy. TA-606 can be used for hypertension research .
    TA-606
  • HY-101390B
    Niguldipine free base

    		Others Cardiovascular Disease
    Niguldipine free base is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine free base can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine free base exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine free base also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine free base on myocardial metabolism is not significant .
    Niguldipine free base
  • HY-111827
    S-1-Propenyl-L-cysteine
    4 Publications Verification

    		 Histamine Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology
    S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model . S-1-Propenyl-L-cysteine exhibits antioxidative efficacy through a NO-dependent BACH1 signaling pathway . S-1-Propenyl-L-cysteine is orally active.
    S-1-Propenyl-L-cysteine
  • HY-114782
    H-Tyr-Tyr-OH

    L-Tyrosyl-L-tyrosine

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    H-Tyr-Tyr-OH (L-Tyrosyl-L-tyrosine) is an antihypertensive peptide. H-Tyr-Tyr-OH inhibits angiotensin I-converting enzyme (ACE) with an IC50 value of 0.028 mg/mL. H-Tyr-Tyr-OH can be used for the research of high blood pressure .
    H-Tyr-Tyr-OH
  • HY-164027
    MyoMed 205

    		Others Others
    MyoMed-205 is an inhibitor targeting the activity of MuRF1. MyoMed-205 prevents early diaphragmatic systolic dysfunction and atrophy due to unilateral diaphragmatic nerve denervation 12 hours later. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed-205 increases levels of a protein that phosphorylates Akt (ser473), an important signaling molecule for muscle growth and maintenance. MyoMed-205 can be used to study and treat diaphragmatic dysfunction and atrophy (DIDD) caused by early apraxia, especially in clinical situations such as diaphragmatic paralysis or mechanical ventilation .
    MyoMed 205
  • HY-111372
    Finerenone
    2 Publications Verification

    BAY 94-8862

    		 Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone
  • HY-111372R
    Finerenone (Standard)

    		Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: